Executive Interviews

81. What's The Outlook From Life Science Operations For 2022 — And Beyond? 12/1/2021

    With the average daily dose of a biologic costing roughly 22 times more than a small molecule, it seems leaders in biopharma manufacturing have never faced a greater challenge. Here’s what 12 of those execs have to say as they look to 2022 and beyond.

82. Jaguar Health's Lisa Conte — An Entrepreneurial Ascent Like No Other 11/1/2021

    Lisa Conte’s idea was to do more efficient drug discovery and development by leveraging the knowledge of “traditional healers.” However, like most entrepreneurial climbs, it would prove arduous, with plenty of slips, trips, and spills along the way.

83. Long Hauler In The Antibiotics Space 11/1/2021

    For Ted Schroeder, CEO of Nabriva Therapeutics, the road of his biopharma career led him into the antibiotics space, a mighty steep climb in the biopharma industry.

84. $4 Billion In 4 Years: The Story Of SpringWorks Therapeutics 10/1/2021

    Saqib Islam was one of the five founding members of SpringWorks Therapeutics, which was spun out of Pfizer in 2017. An atypical startup, the company launched with the rights to four clinical-stage experimental therapies and grew quickly in the next few years.

85. Going Precommercial — From The Commercial World 10/1/2021

    Nancy Lurker, a veteran Big-Pharma marketer, now runs a small biopharma. And she admits, “the business models are very, very different.”

86. 35-Year Biopharma R&D Vet Takes On His Second Startup 9/1/2021

    Norbert Bischofberger, Ph.D., had a good job at Gilead where he had worked for nearly two decades. Then, out of the blue, he found out he was being considered for a CEO position at a small startup called Kronos Bio.

87. What's It Like Being A First-Time Biopharma CEO? 9/1/2021

    In this edited transcript of our June 2021 executive virtual roundtable, three first-time CEOs tell us their tales of the good, the bad, and the ugly related to being CEO.

88. Becoming A Clinical-Stage Biotech 9/1/2021

    A Q&A with Laura Indolfi, CEO and cofounder of PanTher Therapeutics, which recently closed its Series A funding round and is preparing for its first clinical trials.

89. Coming Out Of Stealth Mode: What To Know And Do 8/2/2021

    In Part two of this two-part series, we look at what companies should do to make the exit from stealth mode an effective exchange with the outside world — how to identify and reach investors, influencers, and stakeholders in a company’s pursuit of new treatments for diseases, from rare conditions to widespread medical challenges, some at the scale of public health.

90. From Professor To Regenerative Medicine Company CEO 8/2/2021

    Though she cofounded the company in 2004 and played an active role throughout its growth, until November 2020, Laura Niklason, M.D., Ph.D., had never held a c-level title within it.